Lumida
/IBEX
⌘K
Ibex Ltd

Ibex Ltd

IBEX
$35.39USD-0.17%-0.06 today

MARKET CAP

473.8M

P/E (TTM)

10.0x

FWD P/E

9.6x

DAY RANGE

$35 – $36

52W RANGE

$26
$43

AI Summary

Stalk
StalkMedium

IBEX remains in an early Stage 1 consolidation within a long-term uptrend. Price has repaired its 9/21 EMA regime and is range-bound, suggesting cautious accumulation. Medium-term directional bias is modestly bullish, but short-term timing is neutral, warranting deferred execution into pullbacks around EMA support.

  • Q3 revenue of $164.4M rose 17% YoY, driven by 53.7% health tech growth.
  • Adjusted EPS grew 11% YoY to $0.91, boosting adjusted EBITDA margins.
  • Largest client accounts for 10% of revenue, indicating concentration risk.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

IBEX Limited (NASDAQ: IBEX) is a leading global provider of business process outsourcing (BPO) services, focusing on enhancing customer experience (CX) solutions across various sectors, particularly health tech, fintech, and retail. The company leverages cutting-edge technologies, including artificial intelligence (AI), to differentiate itself in the competitive BPO market. As the demand for integrated and tech-driven services grows, IBEX has positioned itself at the forefront of this transformation, making it a vital player in the evolving landscape of customer experience solutions.

Bull says

  • Q3 revenue of $164.4M rose 17% YoY, driven by 53.7% health tech growth.
  • Adjusted EPS grew 11% YoY to $0.91, boosting adjusted EBITDA margins.
  • 100% client retention and 99.9% revenue retention underscore loyalty.
  • $10.1M share repurchase signals management confidence and strong cash flow.
  • Sierra AI alliance enables scalable AI-powered CX solutions.
  • High earnings yield and strong growth factors suggest attractive returns; volatility elevated.

Bear says

  • Largest client accounts for 10% of revenue, indicating concentration risk.
  • Operational costs in emerging markets may compress margins.
  • Negative dividend yield and weak balance-sheet metrics highlight financial vulnerability.
  • Health tech or fintech downturns could reduce demand for services.
  • Low institutional ownership and small market cap may limit liquidity.
  • International expansion carries regulatory and compliance execution risks.

Investment themes with IBEX

Buybacks +0.48%

Companies repurchasing their own shares

C · JCI · WFC

Earnings Call · Q3 2026 · Mgmt. Guidance

Updated 05-12-2026neutral

Transcript signals

Read full transcript analysis ›